Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Others

Caris Life Sciences (CAI) Change in Cash (2024 - 2026)

Caris Life Sciences has reported Change in Cash over the past 2 years, most recently at $43.1 million for Q4 2025.

For Q4 2025, Change in Cash rose 205.06% year-over-year to $43.1 million; the TTM value through Dec 2025 reached -$34.8 million, changed N/A, while the annual FY2025 figure was $732.0 million, 9026.22% up from the prior year.
Change in Cash for Q4 2025 was $43.1 million at Caris Life Sciences, up from $34.3 million in the prior quarter.
Over five years, Change in Cash peaked at $43.1 million in Q4 2025 and troughed at -$71.2 million in Q3 2024.